Jean F Regal1, Richard M Burwick2, Sherry D Fleming3. 1. Department of Biomedical Sciences, University of Minnesota Medical School, Duluth Campus, 1035 University Dr., Duluth, MN, 55812, USA. jregal@d.umn.edu. 2. Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. Division of Biology, Kansas State University, Manhattan, KS, USA.
Abstract
PURPOSE OF REVIEW: Preeclampsia affects 3-4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. RECENT FINDINGS: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.
PURPOSE OF REVIEW: Preeclampsia affects 3-4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. RECENT FINDINGS: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.
Authors: Scott M Drouin; Meenal Sinha; Georgia Sfyroera; John D Lambris; Rick A Wetsel Journal: Am J Respir Crit Care Med Date: 2006-01-26 Impact factor: 21.405
Authors: Robin L Davisson; Darren S Hoffmann; Genelle M Butz; Gilbert Aldape; Gunther Schlager; David C Merrill; Sanjeev Sethi; Robert M Weiss; James N Bates Journal: Hypertension Date: 2002-02 Impact factor: 10.190
Authors: Tony T Jiang; Vandana Chaturvedi; James M Ertelt; Jeremy M Kinder; Dayna R Clark; Amy M Valent; Lijun Xin; Sing Sing Way Journal: J Immunol Date: 2014-06-01 Impact factor: 5.422
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng Journal: JAMA Date: 2017-04-25 Impact factor: 56.272
Authors: Mikel D Haggadone; Jamison J Grailer; Fatemeh Fattahi; Firas S Zetoune; Peter A Ward Journal: Mediators Inflamm Date: 2016-06-07 Impact factor: 4.711
Authors: Giuseppina Arbore; Erin E West; Rosanne Spolski; Avril A B Robertson; Andreas Klos; Claudia Rheinheimer; Pavel Dutow; Trent M Woodruff; Zu Xi Yu; Luke A O'Neill; Rebecca C Coll; Alan Sher; Warren J Leonard; Jörg Köhl; Pete Monk; Matthew A Cooper; Matthew Arno; Behdad Afzali; Helen J Lachmann; Andrew P Cope; Katrin D Mayer-Barber; Claudia Kemper Journal: Science Date: 2016-06-17 Impact factor: 47.728
Authors: Anna Inkeri Lokki; Jenni Heikkinen-Eloranta; Hanna Jarva; Terhi Saisto; Marja-Liisa Lokki; Hannele Laivuori; Seppo Meri Journal: Front Immunol Date: 2014-07-09 Impact factor: 7.561
Authors: Kenji J Maeda; Kurt C Showmaker; Ashley C Johnson; Michael R Garrett; Jennifer M Sasser Journal: Physiol Genomics Date: 2019-05-24 Impact factor: 3.107
Authors: Muna Saleh; Michele Compagno; Sofia Pihl; Helena Strevens; Barbro Persson; Jonas Wetterö; Bo Nilsson; Christopher Sjöwall Journal: J Clin Med Date: 2022-06-22 Impact factor: 4.964
Authors: Jean F Regal; Jenna M Lund; Cameron R Wing; Kate M Root; Luke McCutcheon; Lynne T Bemis; Jeffrey S Gilbert; Sherry D Fleming Journal: Mol Immunol Date: 2019-07-18 Impact factor: 4.407